Turner Investments’s Sage Therapeutics SAGE Stock Holding History

Turner Investments’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,000	Closed	-$159K	–	202
2017 Q2	$159K	Buy	+2,000	New	+$145K	0.1%	211

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Turner Investments's SAGE Position: Q3 2017 in Review

Turner Investments sold out of Sage Therapeutics (SAGE) in Q3 2017, closing a stake of 2,000 shares — an estimated $159K sold.

Turner Investments first reported a position in SAGE in Q2 2017 and held it in 1 quarter. The position peaked at $159K in Q2 2017. 174 funds tracked by Wall St. Rank hold SAGE as of Q3 2017.

Turner Investments reported no remaining Sage Therapeutics position as of Q3 2017 after selling out during the quarter.
Turner Investments sold 2,000 Sage Therapeutics shares in Q3 2017, an estimated $159K.
Turner Investments first reported a position in Sage Therapeutics in Q2 2017 and held it in 1 quarter.
Turner Investments's Sage Therapeutics position peaked at $159K in Q2 2017.
174 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2017.

Based on Turner Investments's 13F filing for Q3 2017, filed 8 Nov 2017.